BX-795

Catalog No.S1274

Molecular Weight(MW): 591.47

BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC in cell-free assays, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.

Cited by 19 Publications

Nature, 2019, 567(7747):262-266

PubMed: 30842662 ( click the link to review the publication )

Cell, 2019, 176(6):1447-1460

PubMed: 30799039 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(3)

PubMed: 30717477 ( click the link to review the publication )

J Thromb Haemost, 2018, 16(6):1211-1225

PubMed: 29575487 ( click the link to review the publication )

Vet Microbiol, 2018, 227:61-68

PubMed: 30473353 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(20):11622-11642

PubMed: 28977426 ( click the link to review the publication )

Front Cell Infect Microbiol, 2017, 7:169

PubMed: 28529930 ( click the link to review the publication )

J Immunol, 2016, 196(5):2272-82

PubMed: 26826240 ( click the link to review the publication )

J Biol Chem, 2016, 291(20):10904-15

PubMed: 27002159 ( click the link to review the publication )

Tissue Eng Part A, 2016, 22(17-18):1075-85

PubMed: 27477105 ( click the link to review the publication )

Front Cell Infect Microbiol, 2016, 6:182

PubMed: 28018864 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155052

PubMed: 27148873 ( click the link to review the publication )

Am J Reprod Immunol, 2016, 76(5):348-357

PubMed: 27613665 ( click the link to review the publication )

J Biomol Screen, 2016, 10.1177/1087057116656314

PubMed: 27358388 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(49):17438-43

PubMed: 25326420 ( click the link to review the publication )

FEBS J, 2014, 281(17):3816-27

PubMed: 25040165 ( click the link to review the publication )

Virology, 2014, 450-451:182-95

PubMed: 24503081 ( click the link to review the publication )

PLoS One, 2014, 9(11):e112014

PubMed: 25390891 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Description

Targets

PDK-1 ^[1] (Cell-free assay)	c-Kit ^[1] (Cell-free assay)	CDK2/CyclinE ^[1] (Cell-free assay)	Chk1 ^[1] (Cell-free assay)
6 nM	320 nM	430 nM	510 nM

In vitro

BX-795 effectively blocks PDK1 activity in PC-3 cells, as shown by their ability to block phosphorylation of S6K1, Akt, PKCδ, and GSK3β. BX-795 potently inhibits tumor cell growth on plastic with IC50 of 1.6, 1.4, and 1.9 μM for MDA-468, HCT-116 and MiaPaca cells, respectively. In soft agar, BX-795 displays higher growth inhibition with IC50 of 0.72, and 0.25 μM for MDA-468, and PC-3 cells, respectively. ^[1] In addition, BX-795, as an inhibitor of the TBK1/IKKɛ, blocks TBK1- and IKKε-mediated activation of IRF3 and production of IFN-β. ^[2] In platelet physiological responses, BX795 produces inhibitory effect on 2-MeSADP-induced or collagen-induced aggregation, ATP secretion and thromboxane generation. ^[3]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
human MV-4-11 cell	NVfPfGhOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIjtVY5KdmirYnn0bY9vKG:oIHj1cYFvKE2YLUStNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{Pi56IH7N	MoPRV2FPT0WU
KRX cells	NV7Vd\|E5TnWwY4Tpc44h[XO\|YYm=	NXzmPHgyPyCvaX7z	MkC1TY5pcWKrdHnvckBw\iCVVV3PMZRi\2enZDDVUGsyKCi3bnvuc5dvKG:{aXfpckkhc2mwYYPlJIRwdWGrbjDlfJBz\XO\|ZXSgbY4hU1K[IHPlcIx{KHW\|aX7nJHs{OlCfLXfhcY1iNUGWUDDhcoQhdXmnbHnuJIJie2mlIIDyc5RmcW5ic4Xid5Rz[XSnIHnuZ5Vj[XSnZDDmc5IhPyCvaX7z	MnPDNlYzPzV4OEG=
human NKM-1 cell	MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGW1WHpKdmirYnn0bY9vKG:oIHj1cYFvKE6NTT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{PjF7NDFOwG0>	M4TFTnNCVkeHUh?=
human P30-OHK cell	Mn:0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVzqNpNzUW6qaXLpeIlwdiCxZjDoeY1idiCSM{CtU2hMKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImsJGlEPTB;MD60PVY2KM7:TR?=	NIrsZlVUSU6JRWK=
human YH-13 cell	M2\B[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1TtXGlvcGmkaYTpc44hd2ZiaIXtZY4hYUhvMUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlYzQDh6IN88US=>	MWjTRW5ITVJ?
human LXF-289 cell	NFLQOlVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkH5TY5pcWKrdHnvckBw\iCqdX3hckBNYEZvMki5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZkvKEmFNUC9NE43PTZ7MzFOwG0>	MVPTRW5ITVJ?
human BE-13 cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXriZ4E5UW6qaXLpeIlwdiCxZjDoeY1idiCERT2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzB2N{eg{txO	MV7TRW5ITVJ?
human RS4-11 cell	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmTXTY5pcWKrdHnvckBw\iCqdX3hckBTWzRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlczPTl2IN88US=>	NXHV[XVKW0GQR1XS
human A3-KAW cell	M{TmSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGPjVFVKdmirYnn0bY9vKG:oIHj1cYFvKEF\|LVvBW{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzNyNUWg{txO	MkjpV2FPT0WU
human PA-1 cell	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmPhTY5pcWKrdHnvckBw\iCqdX3hckBRSS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD64NFQzOiEQvF2=	MVrTRW5ITVJ?
human ES7 cell	NWjqdXd4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MknPTY5pcWKrdHnvckBw\iCqdX3hckBGWzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkizOVY3KM7:TR?=	MX;TRW5ITVJ?
human ES8 cell	NXrGfZVqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M162SWlvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MD64OFM{PiEQvF2=	NXrVd2FkW0GQR1XS
human SW982 cell	NXTtPI1xT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4D6SmlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7OEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk2OTJ2IN88US=>	M3LxSHNCVkeHUh?=
human VA-ES-BJ cell	M3rG[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2DvO2lvcGmkaYTpc44hd2ZiaIXtZY4hXkFvRWOtRmoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjl6NE[3JO69VQ>?	Mm\RV2FPT0WU
human 697 cell	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVHjWG5{UW6qaXLpeIlwdiCxZjDoeY1idiB4OUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlAyPjJ\|IN88US=>	NVrnR5BWW0GQR1XS
human MOLT-4 cell	M2jsTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkD1TY5pcWKrdHnvckBw\iCqdX3hckBOV0yWLUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA{OjR2IN88US=>	NXnzeYNpW0GQR1XS
human D-283MED cell	MVnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2rzUGlvcGmkaYTpc44hd2ZiaIXtZY4hTC1{OEPNSWQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjB\|OUS4JO6ddQ>?	M2SySHNCVkeHUh?=
human ALL-PO cell	M3vDV2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVrlNnVDUW6qaXLpeIlwdiCxZjDoeY1idiCDTFytVG8h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjB4MEezJO69VQ>?	MXvTRW5ITVJ?
human NB14 cell	M4HBeGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{HNXWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNFYxQDFizszN	NWeyeWNNW0GQR1XS
human NTERA-S-cl-D1 cell	NVyxSFJVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MofKTY5pcWKrdHnvckBw\iCqdX3hckBPXEWUQT3TMYNtNURzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6wO\|c4PSEQvF2=	M{\PeXNCVkeHUh?=
human BFTC-905 cell	MmDCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYPJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4xQDFyMTFOwG0>	MWTTRW5ITVJ?
human H4 cell	NFjROnlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXzJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5zMEKwNUDPxE1?	MmDzV2FPT0WU
human CHP-212 cell	MljOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYXJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlE1ODN5IN88US=>	MnHXV2FPT0WU
human A204 cell	MoTrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4\1dmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNVU1PjdizszN	MUjTRW5ITVJ?
human NB69 cell	Ml;FS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NGToXJBKdmirYnn0bY9vKG:oIHj1cYFvKE6ENkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlE2QDZ3IN88US=>	M3vHfnNCVkeHUh?=
human P12-ICHIKAWA cell	Mn;jS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWjxc5Z3UW6qaXLpeIlwdiCxZjDoeY1idiCSMUKtTWNJUUuDV1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlE5OTdzIN88US=>	NVn3ZnBNW0GQR1XS
human L-363 cell	Mo\ZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYrCT5F7UW6qaXLpeIlwdiCxZjDoeY1idiCOLUO2N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOThzOUeg{txO	NGPhbIpUSU6JRWK=
human ES5 cell	M3Hsc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1T0WWlvcGmkaYTpc44hd2ZiaIXtZY4hTVN3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6xPVM2PCEQvF2=	M1nrcHNCVkeHUh?=
human CAL-51 cell	M2XHWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWLJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC13MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuNlIyPTZizszN	M4HyPHNCVkeHUh?=
human NBsusSR cell	NIT3d4pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1TBVWlvcGmkaYTpc44hd2ZiaIXtZY4hVkK\|dYPTVkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjR3N{ig{txO	MmPQV2FPT0WU
human HOP-92 cell	NFjlTVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NG\ZVFVKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD25NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjd{OUOg{txO	M{LIOXNCVkeHUh?=
human DU-4475 cell	M3q2UWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1jz[WlvcGmkaYTpc44hd2ZiaIXtZY4hTFVvNES3OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjl{NEWg{txO	NIrlNXFUSU6JRWK=
human LB1047-RCC cell	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MX\Jcohq[mm2aX;uJI9nKGi3bXHuJGxDOTB2Nz3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjJ7MkixJO69VQ>?	MlvMV2FPT0WU
human D-566MG cell	NVL0cZBGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NF7QZplKdmirYnn0bY9vKG:oIHj1cYFvKERvNU[2UWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjNyNES4JO69VQ>?	MWnTRW5ITVJ?
human A375 cell	MoD6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NUnYZpQyUW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{ODh3ODFOwG0>	MnTVV2FPT0WU
human ATN-1 cell	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Ml2xTY5pcWKrdHnvckBw\iCqdX3hckBCXE5vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuN\|cyQDVizszN	MnfqV2FPT0WU
human M059J cell	M1PlWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYLJcohq[mm2aX;uJI9nKGi3bXHuJG0xPTmMIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT6zO\|Y2OiEQvF2=	M2\QUnNCVkeHUh?=
human HSC-3 cell	M1jkOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mki1TY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOFQzODhizszN	MknCV2FPT0WU
human DOHH-2 cell	MmjwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVTJcohq[mm2aX;uJI9nKGi3bXHuJGRQUEhvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOFU5OTRizszN	NITpTGpUSU6JRWK=
human G-402 cell	NX3afpNxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MonRTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuOFY2OjVizszN	MkTGV2FPT0WU
human LC-2-ad cell	MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFz6[pBKdmirYnn0bY9vKG:oIHj1cYFvKEyFLUKtZYQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjR5MUOyJO69VQ>?	MUTTRW5ITVJ?
human LOXIMVI cell	NGP4bI1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3TyTGlvcGmkaYTpc44hd2ZiaIXtZY4hVE:[SV3WTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTB3NUKg{txO	M2rqO3NCVkeHUh?=
human DK-MG cell	NVyzOXBRT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1;YT2lvcGmkaYTpc44hd2ZiaIXtZY4hTEtvTVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU4Ojl6IN88US=>	M1:0c3NCVkeHUh?=
human HOS cell	NX\aUGdWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2L6VmlvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT61O\|MxQSEQvF2=	MmHkV2FPT0WU
human BHT-101 cell	MluxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M1raSGlvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTd6N{eg{txO	MWrTRW5ITVJ?
human U-2-OS cell	NHT3[VZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVizbm1HUW6qaXLpeIlwdiCxZjDoeY1idiCXLUKtU3Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjV6OEC2JO69VQ>?	NGXsdFFUSU6JRWK=
human D-423MG cell	NWrMXW4zT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXrJcohq[mm2aX;uJI9nKGi3bXHuJGQuPDJ\|TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYxQDB4IN88US=>	Mn3uV2FPT0WU
human AN3-CA cell	MoLjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4T5XGlvcGmkaYTpc44hd2ZiaIXtZY4hSU5\|LVPBJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43Ozl7MTFOwG0>	MmnGV2FPT0WU
human TE-11 cell	NXi3flZDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVXCfGNCUW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjV{ODFOwG0>	MoX3V2FPT0WU
human SK-NEP-1 cell	NFrIPGpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M161c2lvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTlXQMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjZ3M{e2JO69VQ>?	MVLTRW5ITVJ?
human MG-63 cell	MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NVHLZm5lUW6qaXLpeIlwdiCxZjDoeY1idiCPRz22N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPjh3Nkeg{txO	MXrTRW5ITVJ?
human RH-1 cell	M3HIeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NETPdIRKdmirYnn0bY9vKG:oIHj1cYFvKFKKLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlcxOjd2IN88US=>	MWTTRW5ITVJ?
human MDA-MB-157 cell	NIfPPIxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXzKVZVWUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOTV5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT63NVY4PCEQvF2=	NXn5PFZvW0GQR1XS
human A427 cell	MnjXS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MlvJTY5pcWKrdHnvckBw\iCqdX3hckBCPDJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT63N\|U5QSEQvF2=	MULTRW5ITVJ?
human ES1 cell	NH\UdmhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NF\rbo5KdmirYnn0bY9vKG:oIHj1cYFvKEWVMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuO\|U1PTFizszN	MojwV2FPT0WU
human C32 cell	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWLJcohq[mm2aX;uJI9nKGi3bXHuJGM{OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTFwN{[zPUDPxE1?	NGq1c3lUSU6JRWK=
human LAMA-84 cell	MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1P0fWlvcGmkaYTpc44hd2ZiaIXtZY4hVEGPQT24OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPzZ6N{Kg{txO	MnPpV2FPT0WU
human YKG-1 cell	MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mmr2TY5pcWKrdHnvckBw\iCqdX3hckB[U0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUGuO\|cyOjRizszN	NFfmc2xUSU6JRWK=
human NCI-H1048 cell	MmfKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVrvdHZuUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFExPDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLke4OVA6KM7:TR?=	M3zmcHNCVkeHUh?=
human KS-1 cell	NH;GfXpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXjJcohq[mm2aX;uJI9nKGi3bXHuJGtUNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkiyPVgh\|ryP	NVHZPFQ4W0GQR1XS
human JVM-3 cell	NEXLfmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NH;1bHlKdmirYnn0bY9vKG:oIHj1cYFvKEqYTT2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45PjR7MTFOwG0>	MXvTRW5ITVJ?
human GI-ME-N cell	M1HObGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NEWyNFlKdmirYnn0bY9vKG:oIHj1cYFvKEeLLV3FMW4h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjh4NUOg{txO	MV7TRW5ITVJ?
human GT3TKB cell	M2jvVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2G5TWlvcGmkaYTpc44hd2ZiaIXtZY4hT1R\|VFvCJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45QTZ2MjFOwG0>	M4Dv[nNCVkeHUh?=
human CHL-1 cell	MknzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWTJcohq[mm2aX;uJI9nKGi3bXHuJGNJVC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT65NlM4QSEQvF2=	NGHOPYdUSU6JRWK=
human CHP-134 cell	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYL5e3UyUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNVM1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS57NES2O{DPxE1?	MVzTRW5ITVJ?
human 8-MG-BA cell	MlzTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYrJcohq[mm2aX;uJI9nKGi3bXHuJFguVUdvQlGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlk2PzR2IN88US=>	MWfTRW5ITVJ?
human HO-1-N-1 cell	MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYHJcohq[mm2aX;uJI9nKGi3bXHuJGhQNTFvTj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46PzFzNzFOwG0>	NXryZVA2W0GQR1XS
human SW1088 cell	MofPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXPYPJhYUW6qaXLpeIlwdiCxZjDoeY1idiCVV{GwPFgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjl7NkezJO69VQ>?	NUjtOlRoW0GQR1XS
human SW48 cell	M{HsPWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGTQRmdKdmirYnn0bY9vKG:oIHj1cYFvKFOZNEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlAzODZ5IN88US=>	NIWwZZJUSU6JRWK=
human VM-CUB-1 cell	NGXTfYdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MorCTY5pcWKrdHnvckBw\iCqdX3hckBXVS2FVVKtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODRzMUmg{txO	NWLpN2FNW0GQR1XS
human COLO-800 cell	M2j0cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NFjoNWxKdmirYnn0bY9vKG:oIHj1cYFvKEORTF:tPFAxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5yNUGzOkDPxE1?	MVzTRW5ITVJ?
human TI-73 cell	MmrJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MV;Jcohq[mm2aX;uJI9nKGi3bXHuJHRKNTd\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6xNVM6QSEQvF2=	M4rFRXNCVkeHUh?=
human HN cell	NXLOd2FlT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWfoVXhHUW6qaXLpeIlwdiCxZjDoeY1idiCKTjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNVIyQThizszN	M1uyc3NCVkeHUh?=
human DB cell	NHfmT\|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NI\FPY9KdmirYnn0bY9vKG:oIHj1cYFvKESEIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6xNlY{OSEQvF2=	MV\TRW5ITVJ?
human Ca9-22 cell	MofrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MoTKTY5pcWKrdHnvckBw\iCqdX3hckBE[TlvMkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlEzQDR5IN88US=>	MnSzV2FPT0WU
human A549 cell	NXTsW\|NLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXXJcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkGzPFA5KM7:TR?=	MUfTRW5ITVJ?
human KGN cell	MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NX7UeWZ6UW6qaXLpeIlwdiCxZjDoeY1idiCNR16gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlIzPTl3IN88US=>	NVH0OpdUW0GQR1XS
human BCPAP cell	NV;3XG5TT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2\ucmlvcGmkaYTpc44hd2ZiaIXtZY4hSkOSQWCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI{OTV6IN88US=>	MV;TRW5ITVJ?
human Ramos-2G6-4C10 cell	M2fxSmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NULRfYpWUW6qaXLpeIlwdiCxZjDoeY1idiCUYX3vd{0zTzZvNFOxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjN5NUmg{txO	NFrTZ5FUSU6JRWK=
human OVCAR-5 cell	NV\MfWhsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M361T2lvcGmkaYTpc44hd2ZiaIXtZY4hV1[FQWKtOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjd5M{Sg{txO	M2nyc3NCVkeHUh?=
human KG-1 cell	M3rBWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1;FOWlvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNlc4QTJizszN	NXPVd3k4W0GQR1XS
human CAKI-1 cell	NYPZ[oQ4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXvJcohq[mm2aX;uJI9nKGi3bXHuJGNCU0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNlgxPThizszN	MVnTRW5ITVJ?
human QIMR-WIL cell	NE\6NmZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXvHVWhqUW6qaXLpeIlwdiCxZjDoeY1idiCTSV3SMXdKVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwMki3OFQh\|ryP	MnLYV2FPT0WU
human SW1710 cell	NGP1SYlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MV\Jcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuNlkyPDJizszN	MW\TRW5ITVJ?
human SK-UT-1 cell	MlPBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXfCdXJbUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3VWE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5{OUOzPUDPxE1?	MXzTRW5ITVJ?
human IST-SL1 cell	NG\SRWlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXHJcohq[mm2aX;uJI9nKGi3bXHuJGlUXC2VTEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlMzOTd2IN88US=>	M1nMdnNCVkeHUh?=
human SW962 cell	MlL6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NX\QZY9{UW6qaXLpeIlwdiCxZjDoeY1idiCVV{m2NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOzN5NUeg{txO	NXr0cHE4W0GQR1XS
human EM-2 cell	NUXWcXBuT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEDEZVRKdmirYnn0bY9vKG:oIHj1cYFvKEWPLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlM2OzN5IN88US=>	NH\PXFRUSU6JRWK=
human D-263MG cell	M4LNOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWPJcohq[mm2aX;uJI9nKGi3bXHuJGQuOjZ\|TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlM5OzJ5IN88US=>	NFfPNYZUSU6JRWK=
human T98G cell	M3ewcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MmHqTY5pcWKrdHnvckBw\iCqdX3hckBVQTiJIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6zPFg2PyEQvF2=	MX7TRW5ITVJ?
human CTB-1 cell	NFzX[oxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVjJcohq[mm2aX;uJI9nKGi3bXHuJGNVSi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj6zPVc3OSEQvF2=	NHjUZVdUSU6JRWK=
human Hs-578-T cell	M1\VZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M13ZN2lvcGmkaYTpc44hd2ZiaIXtZY4hUHNvNUe4MXQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjRzNUi3JO69VQ>?	Mlf4V2FPT0WU
human SF126 cell	M{fwcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NEfTbYVKdmirYnn0bY9vKG:oIHj1cYFvKFOIMUK2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk41OzZ{MTFOwG0>	MVXTRW5ITVJ?
human NCI-H460 cell	NXi5W5NTT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWjWfY5RUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFQ3OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwNEO5OVUh\|ryP	MXXTRW5ITVJ?
human NCI-H1755 cell	Mn7US5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MoLKTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3OVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjV2MESzJO69VQ>?	NHniUXhUSU6JRWK=
human HL-60 cell	NIrOd4RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1LkTmlvcGmkaYTpc44hd2ZiaIXtZY4hUExvNkCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlU1OTV7IN88US=>	NGS4VppUSU6JRWK=
human G-401 cell	NGjqcXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUTJcohq[mm2aX;uJI9nKGi3bXHuJGcuPDBzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj61OlA6QSEQvF2=	M{Dib3NCVkeHUh?=
human AGS cell	M4TUUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NW\CbWt6UW6qaXLpeIlwdiCxZjDoeY1idiCDR2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlU3OjV5IN88US=>	MnTNV2FPT0WU
human HuO9 cell	Ml3qS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYjJcohq[mm2aX;uJI9nKGi3bXHuJGh2VzliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkW2OFU3KM7:TR?=	MV;TRW5ITVJ?
human MFE-280 cell	MkPlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnKxTY5pcWKrdHnvckBw\iCqdX3hckBOTkVvMkiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk42PjZ6NjFOwG0>	NInCZ3hUSU6JRWK=
human NCI-H292 cell	Mn2wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVv1WHBiUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwNUe3NlIh\|ryP	NUjvNIZOW0GQR1XS
human HuO-3N1 cell	Mk\5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXTPe4ZCUW6qaXLpeIlwdiCxZjDoeY1idiCKdV:tN24yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi54MEOwO{DPxE1?	M3;zUHNCVkeHUh?=
human ES3 cell	NWX1R3VnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3;DfGlvcGmkaYTpc44hd2ZiaIXtZY4hTVN\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;Mj62NlI5PSEQvF2=	NYLRcIJOW0GQR1XS
human LB2241-RCC cell	MnL2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M3;V[WlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ{MkSxMXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTJwNkmwO\|kh\|ryP	Mn7tV2FPT0WU
human NCI-H1155 cell	M1[5UWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1HvXGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNVU2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi54OUSwOUDPxE1?	NIe5eolUSU6JRWK=
human SW872 cell	NVXjfYVmT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEXwOXZKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9Nk44ODZ5NjFOwG0>	MojHV2FPT0WU
human MHH-ES-1 cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmnFTY5pcWKrdHnvckBw\iCqdX3hckBOUEhvRWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvPzJ4M{Og{txO	MkGyV2FPT0WU
human KYSE-150 cell	M4riVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NELzWFhKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtNVUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi55Mkm3JO69VQ>?	MnPMV2FPT0WU
human MC-IXC cell	M2XPW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NE\GUXVKdmirYnn0bY9vKG:oIHj1cYFvKE2FLVnYR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDl3MzFOwG0>	NF7Bd5BUSU6JRWK=
human HCC1187 cell	NV\a[ndqT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1;s[mlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUG4O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDl4N{eg{txO	M4DafnNCVkeHUh?=
human UMC-11 cell	NYPOU3VkT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUfJcohq[mm2aX;uJI9nKGi3bXHuJHVOSy1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPVA1PzdizszN	NXX6NIp7W0GQR1XS
human NB5 cell	Mlu4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NETkeVJKdmirYnn0bY9vKG:oIHj1cYFvKE6ENTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUKuPVM4OTVizszN	MmjxV2FPT0WU
human A2058 cell	M2W5OWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{HvPGlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlk4QDR2IN88US=>	M1S0dnNCVkeHUh?=
human Becker cell	MmnYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkHnTY5pcWKrdHnvckBw\iCqdX3hckBD\WOtZYKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlAyOTF{IN88US=>	Mnj5V2FPT0WU
human CAS-1 cell	MlTiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M37IXGlvcGmkaYTpc44hd2ZiaIXtZY4hS0GVLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlAyPTZ7IN88US=>	NYDWZlZNW0GQR1XS
human SW780 cell	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mn;FTY5pcWKrdHnvckBw\iCqdX3hckBUXzd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuNlU3ODlizszN	NHm3d2ZUSU6JRWK=
human KM12 cell	NWWzcYYyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1\a[mlvcGmkaYTpc44hd2ZiaIXtZY4hU01zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuN\|AyOzJizszN	MlvxV2FPT0WU
human PC-3 cell	MmHHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4\zUGlvcGmkaYTpc44hd2ZiaIXtZY4hWENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuNVc1OTFizszN	M4jWPXNCVkeHUh?=
human A253 cell	NXG4T2xDT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NF\vNJVKdmirYnn0bY9vKG:oIHj1cYFvKEF{NUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlE5QDl\|IN88US=>	MXnTRW5ITVJ?
human NB10 cell	Mon1S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NULHc3RMUW6qaXLpeIlwdiCxZjDoeY1idiCQQkGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4zOjd5MzFOwG0>	NXjlOYxHW0GQR1XS
human A172 cell	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWrJcohq[mm2aX;uJI9nKGi3bXHuJGEyPzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkS0OVch\|ryP	NHPNPZVUSU6JRWK=
human A498 cell	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M2HENWlvcGmkaYTpc44hd2ZiaIXtZY4hSTR7ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUSuOVY{QDNizszN	MUDTRW5ITVJ?
human SW1573 cell	M1\wTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NES1dWRKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUW3N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvQTB2OUGg{txO	MXXTRW5ITVJ?
human 5637 cell	M3Pqbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MoDyTY5pcWKrdHnvckBw\iCqdX3hckA2PjN5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;OD6wO\|kxPCEQvF2=	MYnTRW5ITVJ?
human A388 cell	MoHBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXPkeJhvUW6qaXLpeIlwdiCxZjDoeY1idiCDM{i4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NlEvOTN7ODFOwG0>	NVvTXpZMW0GQR1XS
human U251 cell	MnjMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWPJcohq[mm2aX;uJI9nKGi3bXHuJHUzPTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{OD6xNVc2KM7:TR?=	NXixW3lYW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-p38 / p38 / p-JNK / JNK / gD-2 ; PubMed: 28112176 Acta Pharmacol Sin BX-795 inhibition on HSV replication attenuated by overexpression of p38/JNK. HeLa cells with or without JNK1 or p38 overexpression were infected with HSV-2 and total cellular protein was prepared for WB analysis. gD-2, the phosphorylation level of p38 MA䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘 pTBK1 / TBK1 / pPLK1 / PLK1; PubMed: 26772203 Mol Cancer Ther TBK1 mediated activation of the mitotic kinase PLK1. SW210.5 cells were treated with indicated TBK1 inhibitors for 1 hour and then exposed to 50 ng/mL of nocodazole for 18 hours. Western blot detected the signaling change using indicated antibodies, and β䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ	28112176 26772203
Growth inhibition assay	Cell viability ; PubMed: 26772203 Mol Cancer Ther Four SCLC cell lines with no MYC amplification were treated with TBK1 inhibitor BX-795 at the titration concentration. Cell viability was performed by CellTiter Glo 4 days after treatment. The growth curve was constructed by GraphPad Prism 6.	26772203

Protocol

Kinase Assay:^[1]	+ Expand Kinase assays: PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μl of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 h at room temperature, we add 25 mM EDTA and spotted a portion of the reaction mixture on Whatman P81 phosphocellulose paper. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a Fuji phosphorimager.
Cell Research:^[1]	+ Expand Cell lines: MDA-468, PC-3, HCT-116 and MiaPaca cells Concentrations: ~10 μM Incubation Time: 72 hours Method: Cells seeded at a low density (1,500–3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal. Results are reported as the average ± S.E. of two or more replicates. (Only for Reference)

Kinase Assay:^[1]

+ Expand

Kinase assays:

PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μl of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-³³P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 h at room temperature, we add 25 mM EDTA and spotted a portion of the reaction mixture on Whatman P81 phosphocellulose paper. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a Fuji phosphorimager.

Cell Research:^[1]

+ Expand

Cell lines: MDA-468, PC-3, HCT-116 and MiaPaca cells
Concentrations: ~10 μM
Incubation Time: 72 hours
Method: Cells seeded at a low density (1,500–3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal. Results are reported as the average ± S.E. of two or more replicates.
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (169.07 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG +2% Tween 80+ddH2O For best results, use promptly after mixing.	4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BX-795 SDF

Molecular Weight	591.47
Formula	C₂₃H₂₆IN₇O₂S
CAS No.	702675-74-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can you suggest an in vivo formulation of S1274 for animal studies?
Answer:
We recommend to use the vehicle 2% DMSO+30% PEG +2% Tween 80+ddH2O for in vivo study.

PDK Signaling Pathway Map

Related PDK Products0

CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.
Dorsomorphin (Compound C) ^New

Dorsomorphin is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.
MHY1485 ^New

MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.
OSU-03012 (AR-12)

OSU-03012 (AR-12) is a potent inhibitor of recombinant PDK-1(phosphoinositide-dependent kinase 1) with IC50 of 5 μM in a cell-free assay and 2-fold increase in potency over OSU-02067.

Features:A derivative of celecoxib with 10-fold greater antitumor activity, but lacks celecoxib's COX-2 inhibitory activity.
BX-912

BX912 is a potent and specific PDK1 inhibitor with IC50 of 12 nM, 9- and 105- fold greater selectivity for PDK1 than PKA and PKC in cell-free assays, respectively. In comparison to GSK3β, selectivity for PDK1 is 600-fold.
GSK2334470

GSK2334470 is a novel PDK1 inhibitor with IC50 of ~10 nM in a cell-free assay, with no activity at other close related AGC-kinases.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 HCl (CT99021) is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.

Choose Your Country or Region

By Signaling Pathways

By product type

BX-795

Cited by 19 Publications

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BX-795 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PDK Signaling Pathway Map

Related PDK Products0

Choose Your Country or Region

By Signaling Pathways

By product type

BX-795

Cited by 19 Publications

Purity & Quality Control

Choose Selective PDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BX-795 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

PDK Signaling Pathway Map

Related PDK Products0

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)